Tagged News
Sapient Launches DynamiQ: Next-Generation Multi-Omics Platform Set to Transform Drug Discovery and Development
- Sapient has launched DynamiQ Insights Engine, an advanced multi-omics and real-world data platform that integrates thousands of protein, metabolite, lipid, and cytokine measures with matched genomic and clinical data.
- The platform contains data from over 56,000 samples collected across multiple timepoints from diverse individuals, making it one of the most deeply phenotyped longitudinal datasets available for biomarker discovery and drug development.
- DynamiQ's ability to track molecular changes over time alongside clinical outcomes enables researchers to better understand disease subtypes, predict treatment responses, and identify patients most likely to benefit from specific therapies.
CN Bio and Pharmaron Partner to Advance Organ-on-a-Chip Technology for Drug Development
- CN Bio has formed a strategic partnership with Pharmaron to validate and integrate its PhysioMimix organ-on-a-chip technology across drug discovery applications, reducing reliance on animal testing.
- The collaboration will initially focus on disease modeling, toxicity testing, and ADME studies, with plans to expand into novel applications addressing unmet needs in pharmaceutical R&D.
- This partnership aligns with recent FDA announcements to phase out animal testing requirements for monoclonal antibodies, as the global organ-on-a-chip market is projected to reach $388 million by 2028.
Archetype Therapeutics to Present AI-Discovered Lung Cancer Drug Candidates at AACR 2025
- Archetype Therapeutics will present in vivo proof-of-concept data for AI-identified small molecules targeting early-stage lung adenocarcinoma at the 2025 AACR Annual Meeting.
- The company's generative AI platform identified novel and repurposed molecules that substantially outperform previously published compounds in preventing lung cancer invasion and metastasis.
- Archetype is partnering with Abzena and Alloy Therapeutics to develop antibody-drug conjugates using clinical-stage and approved targeted therapy molecules discovered by their platform.
- The Archetype platform enables virtual screening of billions of potential drugs per day in genomically-defined patient cohorts, advancing from AI-driven research to compelling in vivo data in just months.
Bayer Partners with ConcertAI to Accelerate Precision Oncology Drug Development Using AI
- Bayer and ConcertAI have entered a multi-year strategic agreement leveraging AI and machine learning to accelerate clinical development in precision oncology.
- The partnership utilizes ConcertAI's Translational360™ platform, which integrates data from over 9 million cancer patient records across the U.S., combining clinical, genomic, and imaging information.
- This collaboration aims to enhance drug discovery by using multi-modal data and AI to better predict treatment responses, potentially delivering precision oncology treatments to patients faster.
FDA Announces Shift from Animal Testing to AI Models, Boosting Recursion Pharmaceuticals Stock 20%
- The FDA announced plans to replace animal testing with AI models and other human-relevant methods for drug development, initially focusing on monoclonal antibodies before expanding to other drug types.
- Recursion Pharmaceuticals stock surged approximately 20% following the FDA announcement, as the company operates one of the largest biopharmaceutical datasets with over 60 petabytes of data for AI-driven drug discovery.
- The regulatory shift could increase interest from other drugmakers in partnering with Recursion, which already collaborates with four major pharmaceutical companies including Bayer, Merck KGaA, Genentech, and Sanofi.
AI and Data Collaboration: Key to Advancing Cell Therapy in Biopharma Industry
- Cellular Origins CEO Edwin Stone highlights the challenge of proprietary data silos hindering AI and machine learning implementation in biopharma despite their potential to advance patient care.
- The biopharma industry faces a critical decision between competitive isolation and collaborative data sharing that could accelerate breakthroughs in cell therapy development.
- AI and machine learning technologies are making significant impacts on drug discovery, particularly in virtual and software environments where they've found their initial applications.
New Antibiotic Class Discovered in Soil Sample Could Combat Drug-Resistant Bacteria
- Researchers have identified lariocidin, the first new class of antibiotics to reach the market in nearly 30 years, discovered in bacteria from backyard soil samples.
- The novel molecule targets bacterial ribosomes with a unique mechanism of action, showing effectiveness against both Gram-positive and Gram-negative bacteria, including WHO-priority drug-resistant pathogens.
- Lariocidin demonstrated no toxicity to human cells in initial testing, representing a significant breakthrough in the global fight against antimicrobial resistance, which causes approximately 4.95 million deaths annually.
Amphista Therapeutics Advances Novel BRD9 Degraders Using Proprietary Targeted Glue Technology
- Amphista Therapeutics has developed a novel mechanism for BRD9 degradation using its proprietary Targeted Glue® technology, which recruits DCAF16 E3 ligase instead of traditional CRBN or VHL approaches.
- The company's Eclipsys® platform enables the rational design of orally bioavailable protein degraders with superior drug-like properties, demonstrating rapid, deep, and persistent degradation of BRD9, an emerging target in Acute Myeloid Leukemia.
- Amphista plans to advance its BRD9 degrader into clinical trials in 2026, potentially offering a first-in-class therapeutic option with performance characteristics beyond the limitations of current targeted protein degradation approaches.
Momentum Biotechnologies Acquires OmicScouts to Expand Mass Spectrometry-Based Drug Discovery Platform
- Momentum Biotechnologies has completed the acquisition of Munich-based OmicScouts GmbH, a leader in mass spectrometry-based proteomics, to enhance its drug discovery service offerings.
- The acquisition provides Momentum with access to well-validated proteomic assays that enable clients to progress from high-throughput screening to cell-based assays and biomarker discovery.
- OmicScouts' chemoproteomic capabilities will help close the gap between biochemical hit identification and downstream preclinical assays, addressing long-standing client requests.
- The transaction enables immediate geographic expansion into the European market and strengthens Momentum's position in providing comprehensive mass spectrometry solutions to biopharmaceutical companies.
Regeneron Leads $60 Million Consortium to Accelerate UK Biobank Genome Sequencing for Alzheimer's and Parkinson's Drug Discovery
- Regeneron has formed a consortium with AbbVie, Alnylam, AstraZeneca, Biogen, and Pfizer, with each company committing $10 million to accelerate sequencing of 500,000 UK Biobank genomes by end of 2019.
- The project aims to identify new biological targets for drug development, particularly for neurological diseases like Alzheimer's and Parkinson's, where current failure rates exceed 90%.
- Regeneron's automated sequencing capabilities through its Genetics Center have dramatically reduced processing time, potentially revolutionizing drug discovery by linking genetic data with health records from 500,000 volunteers.
- After an exclusive access period for consortium members, all sequencing data and research findings will be made publicly available to the broader scientific community.